Theranostic cobalt-55/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry

• Published in: Nuclear medicine and biology 2023-03, Vol.118-119, p.108329-108329, Article 108329
• Main Authors: Lin, Wilson, Aluicio-Sarduy, Eduardo, Houson, Hailey A., Barnhart, Todd E., Tekin, Volkan, Jeffery, Justin J., Weichmann, Ashley M., Barrett, Kendall E., Lapi, Suzanne E., Engle, Jonathan W.
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Alpha particles; Alpha rays; Animal models; Animals; Auger electron; Biocompatibility; Cancer; Cobalt; Cobalt-55/58m; Cytotoxicity; Dosage; Dosimeters; Dosimetry; Effectiveness; Emissions; Female; Histology; Humans; In vivo methods and tests; Inoculation; Internalization; Kidneys; Liquid chromatography; Mice; Mice, Nude; Neurotensin; Neurotensin - metabolism; Neurotensin - therapeutic use; Pharmacokinetics; Pilot Projects; Precision Medicine; Radiation; Radiation dosage; Radiation therapy; Radioactive emissions; Radiochemical analysis; Receptors; Receptors, Neurotensin - metabolism; Targeted radionuclide therapy; Theranostic; Toxicity; Tumors; Unit activity; Xenografts
• ISSN: 0969-8051; 1872-9614
• DOI: 10.1016/j.nucmedbio.2023.108329

Neurotensin receptor 1 (NTSR1) can stimulate tumor proliferation through neurotensin (NTS) activation and are overexpressed by a variety of cancers. The high binding affinity of NTS/NTSR1 makes radiolabeled NTS derivatives interesting for cancer diagnosis and staging. Internalization of NTS/NTSR1 also suggests therapeutic application with high LET alpha particles and low energy electrons. We investigated the therapeutic efficacy of [58mCo]Co-NOTA-NT-20.3 in vivo using murine models xenografted with NTSR1-positive HT29 human colorectal adenocarcinoma cells, and utilized [55Co]Co-NOTA-NT-20.3 for dosimetry. Targeting properties and cytotoxicity of [55/58mCo]Co-NOTA-NT-20.3 were assessed with HT29 cells. Female nude mice were xenografted with HT29 tumors and administered [55Co or 58mCo]Co-NOTA-NT-20.3 to evaluate pharmacokinetics or for therapy, respectively. Dosimetry calculations followed the Medical Internal Radiation Dose (MIRD) formalism and human absorbed dose rate per unit activity were obtained from OpenDose. The pilot therapy study consisted of two groups (each N = 3) receiving 110 ± 15 MBq and 26 ± 6 MBq [58mCo]Co-NOTA-NT-20.3 one week after tumor inoculation, and control (N = 3). Tumor sizes and masses were measured twice a week after therapy. Complete blood count and kidney histology were also performed to assess toxicity. HPLC measured radiochemical purity of [55,58mCo]Co-NOTA-NT-20.3 > 99 %. Labeled compounds retained NTS targeting properties. [58mCo]Co-NOTA-NT-20.3 exhibited cytotoxicity for HT29 cells and was >15× more potent than [58mCo]CoCl2. Xenografted tumors responded modestly to administered doses, but mice showed no signs of radiotoxicity. Absorbed dose to tumor and kidney with 110 MBq [58mCo]Co-NOTA-NT-20.3 were 0.6 Gy and 0.8 Gy, respectively, and other organs received less than half of the absorbed dose to tumor. Off-target radiation dose from cobalt-58g was small but reduces the therapeutic window. The enhanced in vitro cytotoxicity and high tumor-to-background led us to investigate the therapeutic efficacy of [58mCo]Co-NOTA-NT-20.3 in vivo. Although we were unable to induce tumor response commensurate with [177Lu]Lu-NT127 (NLys-Lys-Pro-Tyr-Tle-Leu) studies involving similar time-integrated activity, the absence of observed toxicity may constitute an opportunity for targeting vectors with improved uptake and/or retention to avoid the aftereffects of other high-LET radioactive emissions. Future studies with higher uptake, activity an